In the April 22 Federal Register, FDA announced the withdrawal of three new drug applications ("NDAs") and 41 abbreviated new drug applications ("ANDAs") at the request of the application holders because they are no longer marketing these pharmaceuticals. For more information about the withdrawn applications, see Table 1 in the Federal Register issue.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
